Vera Therapeutics, Inc.’s VERA share price has surged by 6.17%, which has investors questioning if this is right time to sell.

BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of ...

In a report released today, Vamil Divan from Guggenheim reiterated a Buy rating on Vera Therapeutics (VERA – Research Report), with a price ...

Vera Therapeutics (VERA) announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA ...

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $41.74 ...

Get the next trade alert free. Vera Therapeutics, Inc. VERA said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients ...

BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting ...

Highlights,Wellington Management Group LLP reduced its holdings in Vera Therapeutics during the fourth quarter.,Schroder Investment Management and Pictet Asset Management increased their equity ...

Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN ...